TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22196768
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of PF-03654746 plus 60 mg of fexofenadine (group 2)
Study: 22196768
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of fexofenadine/120 mg of pseudoephedrine (group 3)
Study: 15776773
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac)
Study: 15776773
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin 1% benzoyl peroxide 5% gel (Duac) in combination with oral doxycycline hyclate (Doryx) and adapalene gel (Differin)
Study: 12005454
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid-based lipid emulsion (fish oil, 10%; 200 mL/d)
Study: 12005454
Drug: n-6 lipid
Normalized name: 18:3 (n-6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-6 lipid emulsion (soybean oil, 10%; 200 mL/d)
Study: 10350383
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg od
Study: 10350383
Drug: Levofloxacin 250
Normalized name: levofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 250 mg od
Study: 10350383
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg bd
Study: 2332608
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prazepam in liquid drops
Study: 2332608
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prazepam in tablets
Study: 7266731
Drug: Choline chloride
Normalized name: Choline Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline chloride (2 g QID)
Study: 31928963
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitagliptin daily for 3 consecutive cycles
Study: 31928963
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo capsules
Study: 15365580
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or desipramine (active treatment) for 8 weeks
Study: 10874061
Drug: Antiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic therapy guided by electrophysiologic testing
Study: 1552468
Drug: Minocycline periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline periodontal formulation
Study: 1552468
Drug: Placebo periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo periodontal formulation
Study: 3874932
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate with citrovorum factor rescue (MTX-CF)
Study: 26483177
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of omalizumab
Study: 26483177
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of omalizumab
Study: 26483177
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of omalizumab
Study: 24567516
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg once weekly (CIL1W) + PFE
Study: 24567516
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg twice weekly (CIL2W) + PFE
Study: 16213325
Drug: CsA-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA-based treatment (n = 73)
Study: 16213325
Drug: Tacrolimus-based treatment
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus-based treatment (n = 47)
Study: 8574272
Drug: ICI D7114
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI D7114 (150 mg/day)
Study: 23677386
Drug: In SHAPE
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In SHAPE program (one year of weekly sessions with a fitness trainer plus a fitness club membership)
Study: 19264687
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg administered in five monthly infusions)
Study: 17889778
Drug: Intracameral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral cefuroxime treatment
Study: 9643742
Drug: rhGH (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (2 IU daily)
Study: 3169118
Drug: cimetidine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (1.2 g daily)
Study: 3169118
Drug: ranitidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (0.3 g daily)
Study: 29782479
Drug: Multicomponent balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent balance and resistance training intervention (once weekly supervised group sessions with home sessions encouraged twice weekly)
Study: 29920171
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of LARC
Study: 21876061
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg micafungin
Study: 21876061
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg micafungin
Study: 21876061
Drug: Micafungin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (both doses)
Study: 10729306
Drug: Sub‐Tenon's block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 + 30 IU/ml of hyaluronidase
Study: 10729306
Drug: Sub‐Tenon's block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 alone
Study: 1390305
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (rIFN alfa‐2a + VLB)
Study: 1390305
Drug: Monotherapy (rIFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (rIFN alfa‐2a)
Study: 3902068
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase infusion
Study: 29595659
Drug: Radial artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radial artery pressure pulse wave treatment in stroke patients with hemiplegia
Study: 29081178
Drug: Weight management
Normalized name: Estroven Weight Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight management guidance and adjusted diuretic drugs regimen based on body weight changes
Study: 26314275
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg fortnightly after induction)
Study: 26314275
Drug: Thiopurines (azathioprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopurines (azathioprine 2 mg/kg/day or mercaptopurine 1.5 mg/kg/day)
Study: 23216710
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) thromboprophylaxis
Study: 23216710
Drug: Strong IgG
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong IgG antibodies (≥ 1.0 OD units and ≥ 2× baseline)
Study: 23216710
Drug: No strong
Approvals — FDA: no, EMA: no, PMDA: no
Description: No strong IgG antibodies
Study: 23216710
Drug: Postoperative anti-PF4/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative anti-PF4/heparin IgG responses
Study: 21624100
Drug: Adrenaline (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (0.4 μg min m(‐2))
Study: 18945995
Drug: Cinacalcet and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet and low-dose vitamin D (Cinacalcet-D)
Study: 16467100
Drug: Gefitinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 500 mg plus sirolimus 5 mg (not on EIAEDs)
Study: 16467100
Drug: Gefitinib 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 1000 mg plus sirolimus 10 mg (on EIAEDs)
Study: 11314676
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine (100 mg/70 kg)
Study: 3809244
Drug: L-tryptophan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (4 tablets of 500 mg/day for 14 days)
Study: 3809244
Drug: Phenylalanine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylalanine (4 tablets of 500 mg/day for 14 days)
Study: 3809244
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 placebo tablets/day for 14 days)
Study: 27678426
Drug: Low advanced
Normalized name: ALCOHOL 75 in 100 TOPICAL CLOTH [Mellow advanced alcohol wipes 50wipes 01]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low advanced glycation end products diet (L‐dAGEs)
Study: 11709789
Drug: BBG2Na (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBG2Na (all doses)
Study: 9051434
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Study: 8091174
Drug: Lidocaine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2.0 ml 2%)
Study: 8091174
Drug: Articaine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine (2.0 ml 4%)
Study: 3592320
Drug: 12-hour cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-hour cefazolin (4 intravenous injections of 1 g cefazolin over 12 hours)
Study: 3592320
Drug: 36-hour cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36-hour cefazolin (12 doses over 36 hours)
Study: 12486618
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice daily
Study: 29502160
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) for BMS
Study: 29502160
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) for SOB
Study: 30102967
Drug: Lurasidone 20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20-60 mg/day
Study: 23883379
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg semagacestat
Study: 26948580
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg semagacestat
Study: 19655819
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with olmesartan medoxomil/HCTZ 20/25 mg/day
Study: 19655819
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with olmesartan medoxomil/HCTZ 40/12.5 mg/day
Study: 19655819
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with olmesartan medoxomil/HCTZ 40/25 mg/day
Study: 19655819
Drug: HCTZ 12.5
Normalized name: HCTZ 12.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 12.5 or 25 mg/day
Study: 19655819
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 10, 20, or 40 mg/day
Study: 16273313
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) + BCNU + standard radiation therapy (SRT)
Study: 16273313
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) + BCNU + accelerated radiation therapy (ART)
Study: 16273313
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) + standard radiation therapy (SRT)
Study: 16273313
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) + accelerated radiation therapy (ART)
Study: 11259892
Drug: Mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 1% (1 mL/kg)
Study: 11259892
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% (1 mL/kg)
Study: 11259892
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of mepivacaine 1% and bupivacaine 0.25% (0.5 mL/kg each)
Study: 26214725
Drug: Riluzole 50
Normalized name: riluzole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole 50 mg twice a day
Study: 22233243
Drug: Trauma Affect
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Study: 19469601
Drug: Supportive Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Group Therapy (SGT)
Study: 21301135
Drug: Midodrine hydrochloride
Normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine hydrochloride plus conventional therapy
Study: 21301135
Drug: Metoprolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol plus conventional therapy
Study: 12183280
Drug: Voriconazole at
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole at 10.4 +/- 4.3 micro g/ml
Study: 11477859
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus Chinese herbal medicine
Study: 2514651
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg daily for 3 months
Study: 2514651
Drug: Cicletanine 100
Normalized name: cicletanine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 100 mg daily for 3 months
Study: 26705233
Drug: Sodium Hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Hyaluronate Gel (SHG group)
Study: 23117218
Drug: Adjuvant Occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Occupational Therapy (OT)
Study: 21048770
Drug: diet+PS (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet+PS (2 g/day of phytosterols)
Study: 18506005
Drug: RB006 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB006 (15 mg)
Study: 18506005
Drug: RB006 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB006 (30 mg)
Study: 18506005
Drug: RB006 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB006 (50 mg)
Study: 18506005
Drug: RB006 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB006 (75 mg)
Study: 7979564
Drug: Pulsatile oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile oxytocin infusion
Study: 8970215
Drug: Amoxicillin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (20 mg/kg once daily)
Study: 7982173
Drug: OK-432 (intratumoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (intratumoral injection)
Study: 6385693
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and Tobramycin with peak levels of 7 micrograms/ml or greater
Study: 6385693
Drug: Amikacin with
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin with peak levels of 28 micrograms/ml or greater
Study: 6385693
Drug: Overall mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall mean peak levels of 6 micrograms/ml or greater for Gentamicin and Tobramycin
Study: 6385693
Drug: Overall mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall mean peak levels of 24 micrograms/ml or greater for Amikacin
Study: 29368187
Drug: Fluvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin with green tea extract (GTE) containing 150 mg of EGCG
Study: 11220429
Drug: Dexamethasone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2.5 mg
Study: 25603389
Drug: Dexamethasone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5.0 mg
Study: 25603389
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.0 mg dexamethasone)
Study: 24411757
Drug: Orlistat and
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat and sibutramine treatment
Study: 18188033
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg twice daily)
Study: 18188033
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g three times a day)
Study: 16763848
Drug: ADCON‐L Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON‐L Gel (ALG)
Study: 15230300
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose glucocorticoids and immunosuppressive agents
Study: 12439362
Drug: Aggressive saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive saline hydration with the aim of keeping urine output over 150 mL/hour
Study: 12439362
Drug: Low-osmolality contrast
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-osmolality contrast agents with minimal volume
Study: 12439362
Drug: Dopamine DA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine DA1 agonist fenoldopam
Study: 7962669
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg S(‐)‐atenolol (SATN)
Study: 7962669
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg racemic atenolol (RSATN)
Study: 8949760
Drug: Neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron therapy
Study: 26202325
Drug: Robot-supported upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-supported upper limb training (3 weekly sessions of 30 min for 8 weeks)
Study: 18194307
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with bypassing agents (FEIBA and NovoSeven)
Study: 18194307
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with one bypassing agent (effective)
Study: 17165494
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus antiasthma agents
Study: 17165494
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antiasthma agents only)
Study: 53554
Drug: Cimetidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 0.8 g/day
Study: 7015989
Drug: Glycopyrrolate 4
Normalized name: GLYCOPYRROLATE 4 mg in 20 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 4 mg/day
Study: 30073290
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily for 8 weeks
Study: 16606645
Drug: Single DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single DMARD treatment with or without prednisolone (single group)
Study: 16606645
Drug: Combination DMARD
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination DMARD treatment with prednisolone (combination group)
Study: 10385132
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) 40 mg, three times daily orally for 2 days
Study: 1760831
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sustained-release IS-5-MN
Study: 1760831
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg sustained-release IS-5-MN
Study: 1760831
Drug: Elantan Long
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elantan Long (50 mg sustained-release IS-5-MN)
Study: 6760653
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 100 mg twice daily for 12 weeks
Study: 24439984
Drug: Trandolapril 22
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril 22 mg daily
Study: 16873938
Drug: CoQ(10) supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) supplementation (100 mg tid for 4 weeks)
Study: 12424684
Drug: Cefixime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (2 mg/kg bodyweight)
Study: 30726689
Drug: Omadacycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omadacycline (100 mg IV every 12 hours for two doses, then 100 mg IV every 24 hours; transition to oral 300 mg every 24 hours after 3 days allowed)
Study: 30726689
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg IV every 12 hours; transition to oral 600 mg every 12 hours after 3 days allowed)
Study: 29856291
Drug: Octreotide used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide used when other therapies failed; previously prescribed octreotide for this clinical indication.
Study: 26563147
Drug: Motivational Interviewing/Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing/Cognitive Behavioral Therapy (MI-CBT)
Study: 23127770
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate brachytherapy (HDRB) boost
Study: 23127770
Drug: Adjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant androgen suppression, bisphosphonates, and increasing EBRT dose
Study: 20927698
Drug: Zonisamide (400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (400-600 mg/day tapering to 100-300 mg/day)
Study: 20927698
Drug: Diazepam (130-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (130-50 mg/day tapering to 5-15 mg/day)
Study: 18372685
Drug: Daily exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exposure to a +Gz acceleration gradient
Study: 15791505
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of fluoroquinolone prophylaxis